U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT06917079) titled 'Open-label Study of BBO-11818 in Adult Subjects With KRAS Mutant Cancer' on April 01.
Brief Summary: A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
Study Start Date: March 31
Study Type: INTERVENTIONAL
Condition:
Non-Small Cell Lung Cancer
NSCLC
PDAC - Pancreatic Ductal Adenocarcinoma
CRC (Colorectal Cancer)
Metastatic Non-Small Lung Cell Cancer
Metastatic Colorectal Cancer (CRC)
KRAS G12A
KRAS G12C
KRAS G12D
KRAS G12S
KRAS G12V
Metastatic Pancreatic Ductal Adenocarcinoma
Ad...